Employees: 1,078
Size Beijing Chunlizhengda Medical Instruments (1858.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $631M, the 689th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.21 on 18 Nov 2026.
Performance Over six months the shares fell 28.2%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue fell 9.0% over the last twelve months (peer median +17.8%); the operating margin is 30.7% (peer median 9.5%).
Valuation It trades at 8.5× forward earnings against a peer median of 27.9× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.0 points above its cost of capital (8.5% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.04B | HK$1.13B | HK$867M | HK$1.32B | HK$1.39B |
| Revenue growth | — | +30% | -34% | -5% | — |
| Gross profit | HK$679M | HK$712M | HK$551M | HK$931M | HK$1.03B |
| EBITDA | n/a | HK$334M | HK$136M | HK$323M | HK$358M |
| Net income | HK$305M | HK$296M | HK$136M | HK$307M | HK$358M |
| Free cash flow | HK$360M | HK$392M | -HK$33.0M | HK$553M | HK$50.4M |
| Capital expenditure | HK$48.5M | HK$64.1M | HK$53.3M | HK$36.7M | HK$29.0M |
| Total debt | HK$2.80M | HK$4.20M | HK$978,049 | HK$14.1M | HK$20.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1858.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -1.9% | 9th highest of 19 |
| 6-month return | -28.2% | -6.6% | 4th lowest of 19 |
| Distance from 52-week high | -64.5% | -23.9% | 2nd lowest of 20 |
| Revenue growth (TTM) | -9.0% | +17.8% | 3rd lowest of 20 |
| Operating margin | 30.7% | 9.5% | 3rd highest of 20 |
| Forward P/E | 8.5× | 27.9× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -9.5% | 7.5% | 2nd least demanding of 13 |
| Growth delivered (Del g) | +1.5% | +14.3% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | -11.0 pp | -9.8 pp | 7th least demanding of 13 |
| ROIC minus cost of capital | +18.0 pp | +2.0 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $631M | -28% | -9% | 31% | 8.5× | -9.5% | +1.5% |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 10.7× | n/a | n/a |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 13.8× | 0.2% | +47.5% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 26.0× | 6.6% | -1.9% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 39.0× | 10.1% | +14.2% |
| Delcath Systems DCTH | United States | $685M | +75% | +38% | 5% | 358.9× | 33.4% | +120.2% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | n/a | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Shenzhen Lifotronic Technology 688389.SS | China | $692M | -14% | +14% | 13% | 29.9× | 11.6% | +13.3% |